Bionano Genomics, Inc. (BNGO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bionano Genomics, Inc.

Cue Biopharma, Inc.

Immunome, Inc.

NGM Biopharmaceuticals, Inc.

Aadi Bioscience, Inc.

Armata Pharmaceuticals, Inc.

Sangamo Therapeutics, Inc.

IO Biotech, Inc.

Cyteir Therapeutics, Inc.

Anixa Biosciences, Inc.

Omega Therapeutics, Inc.

Why is Bionano Genomics, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD -26.37 MM
RAW MATERIAL COST(Y) Fallen by -56.97% (YoY)
INVENTORY TURNOVER RATIO(HY) Highest at 1.85 times

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -88.46%, its profits have risen by 43%

MFs have decreased holdings this quarter and now hold 1.92% of the company

Below par performance in long term as well as near term

Along with generating -88.46% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bionano Genomics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bionano Genomics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Bionano Genomics, Inc.

-88.05%

-0.84

114.75%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

26.64%

EBIT Growth (5y)

-30.39%

EBIT to Interest (avg)

-68.10

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.34

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.56%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.26

EV to EBIT

0.03

EV to EBITDA

0.03

EV to Capital Employed

-0.05

EV to Sales

-0.06

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-142.04%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -26.37 MM

RAW MATERIAL COST(Y)

Fallen by -56.97% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.85 times

DEBTORS TURNOVER RATIO(HY)

Highest at 5.57 times

OPERATING PROFIT(Q)

Highest at USD -5.47 MM

OPERATING PROFIT MARGIN(Q)

Highest at -81.26 %

PRE-TAX PROFIT(Q)

Highest at USD -6.26 MM

NET PROFIT(Q)

Highest at USD -6.27 MM

-5What is not working for the Company

NET SALES(HY)

At USD 13.19 MM has Grown at -20.25%

Here's what is working for Bionano Genomics, Inc.

Operating Cash Flow

Highest at USD -26.37 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -5.47 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -81.26 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -6.26 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -6.26 MM has Grown at 69.3%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -6.27 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Net Profit

At USD -6.27 MM has Grown at 69.29%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 1.85 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 5.57 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -56.97% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Bionano Genomics, Inc.

Net Sales

At USD 13.19 MM has Grown at -20.25%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)